FDA's TEMPO Pilot Speeds Up Safe Digital Health Device Access
Published Date: 12/8/2025
Notice
Summary
The FDA is launching the TEMPO pilot to help get cool digital health devices to patients faster while keeping safety a top priority. Starting January 2, 2026, device makers can apply to join this program, which ties payments to real health improvements for people with chronic diseases. This means better care, new tech, and smarter spending for patients and providers alike!
Analyzed Economic Effects
5 provisions identified: 3 benefits, 1 costs, 1 mixed.
Possible Enforcement Discretion for Participants
Manufacturers may ask FDA to exercise enforcement discretion so FDA will not enforce certain legal requirements when their device is offered to or by CMMI ACCESS participants for an intended use to improve patient outcomes. FDA lists examples such as premarket authorization requirements, investigational device exemption (IDE) requirements, and requirements under 21 CFR parts 50 and 56.
Required Real-World Data Collection and Reporting
Manufacturers participating in the TEMPO pilot are expected to collect real-world data (RWD) about their device's intended use, share those data with FDA during participation, and use the data to seek marketing authorization. FDA also requests proposed interim reporting (for example, every 6 months) to report adverse events, new risks, and progress.
Limited US-Based Participant Slots
FDA currently expects to select up to about ten manufacturers based in the United States in each of four clinical use areas for the TEMPO pilot. FDA intends to select U.S.-based manufacturers to facilitate oversight such as inspections and access to records.
Pilot Focus on Four Clinical Use Areas
FDA will consider devices intended for clinician-supervised outpatient treatment in these four clinical use areas: (1) early cardio-kidney-metabolic (hypertension, dyslipidemia, obesity or overweight with marker of central obesity, or prediabetes); (2) cardio-kidney-metabolic (diabetes, chronic kidney disease, or atherosclerotic cardiovascular disease); (3) musculoskeletal (chronic musculoskeletal pain); and (4) behavioral health (depression or anxiety).
Applications Open January 2, 2026
If you make digital health devices, you can submit a "Statement of Interest for Participation in the TEMPO Pilot" starting January 2, 2026. FDA says it will begin follow-up requests to potential participants around March 2, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2025-22188 — Agency Information Collection Activities: Proposed Collection; Comment Request
The Centers for Medicare & Medicaid Services (CMS) wants your thoughts on their plan to collect some info from the public. They’re asking for comments by February 6, 2026, to make sure the process is clear, useful, and not too much work. This affects anyone who might provide info to CMS and helps keep things running smoothly without wasting time or money.
Next: 2025-22191 — Agency Information Collection Activities: Requests for Comments; Clearance of Renewed Approval of Information Collection: FAA Advisory Circular 120-119, Voluntary Safety Management System for Other Regulated Entities Transporting Dangerous Goods by Air
The FAA is renewing approval for a voluntary safety program that helps companies safely transport dangerous goods by air. This affects businesses that choose to follow FAA safety guidelines and submit their safety plans for review. Comments on this renewal are open until January 7, 2026, with no new fees or major changes involved.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in